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Background:Varicose veins and other vascular abnormalities are common clinical entities. Treatment options include vein
stripping, sclerotherapy, and endovenous laser treatment, but all involve some degree of invasive intervention. The
purpose of this study was to determine ex vivo the effectiveness of a novel hand-held, battery-operated, high-intensity
focused ultrasound (HIFU) device for transcutaneous venous ablation.
Methods: The ultrasound device is 14 9 4 cm, weighs 650 g, and is powered by 4 lithium ion battery packs. An ex vivo
testing platform consisting of two different models comprised of sequentially layered skin-muscle-vein or skin-fat-vein
was developed, and specimens were treated with HIFU. The tissues were then disassembled, imaged, and processed for
histology. The luminal cross-sectional area of vein that had been treated with HIFU and nontreated controls were
measured, and the values presented as median and interquartile range (IQR). The values were compared using aWilcoxon
rank-sum test, and statistical significance was set at P < .05.
Results: On gross and histologic examination, veins that had been treated with HIFU showed evidence of coagulation
necrosis. The surface of the muscle in direct contact with the vein had a pinpoint area of coagulation, whereas the adjacent
fat appeared undisturbed; the skin, fat, and the surface of the muscle in contact with the transducer remained completely
unaffected. The cross-sectional area was 3.79 mm2 (IQR, 3.38-4.22) of the control vein lumen and 0.16 mm2 (IQR,
0.04-0.39) in those that had been treated with HIFU (P  .0304).
Conclusion: This inexpensive, portable HIFU device has the potential to allow clinicians to easily perform venous ablation
in a manner that is entirely noninvasive and without the expense or inconvenience of large, complicated devices. This
device represents a significant step forward in the development of new applications for HIFU technology. (J Vasc Surg
2010;51:707-11.)
Clinical Relevance: Although sclerotherapy, radiofrequency ablation, and endovenous laser treatment are less invasive
than previous surgical treatments for varicose veins, they are still invasive procedures and have concomitant risks,
complications, and expenses. The development of a transcutaneous, noninvasive treatment modality holds significant
promise for the treatment of varicose veins and venous malformations.Varicose veins affect approximately 30 million Ameri-
cans.1 The underlying etiology of this condition invariably
involves venous valvular incompetence, and if untreated,
varicosities and the concomitant venous hypertension can
lead to significant morbidity in addition to an unpleasant
cosmetic appearance. If lifestyle modification and other
conservative treatments are not successful, a number of
surgical options may be offered. Vein stripping and vein
ligation had been commonly performed procedures but
have been largely supplanted by less invasive methods,
including sclerotherapy, radiofrequency ablation, and en-
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doi:10.1016/j.jvs.2009.10.049dovenous thermal ablation (EVLT).2,3 Even these mini-
mally invasive methods, however, require a surgical proce-
dure and carry the risk of complications such as phlebitis,
bruising, blood clots, skin ulceration, and infection.4 Al-
though much less common, venous malformations may
also cause significant morbidity and are currently treated
primarily by the same minimally invasive techniques.5
Ultrasound (US) imaging has been available for many
decades as a diagnostic modality that allows for visualiza-
tion of tissues by penetrating a medium and measuring the
reflection.6 In addition to the commonly used diagnostic
applications, this technology has many potential therapeu-
tic applications. Because the transducer of this high-inten-
sity ultrasound (HIFU) device is concave, the beam of
acoustic waves is conical and thereby focuses the energy
onto a single focal point, inducing precise tissue necrosis
without any untoward effect on surrounding and interven-
ing tissue. If it is necessary to thermally ablate a larger
volume of tissue, the beam is focused at multiple locations.
HIFU is currently being used in conjunction withmagnetic
resonance imaging and US imaging in select clinical situa-
tions for the treatment of uterine fibroids and lipomas, the
delivery of drugs to the brain, and the sealing of blood
vessels.7-11
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able, with intensity ranging from 0.5 to 9000 W/cm2, and
with most requiring some degree of invasiveness to apply the
US beam to the tissue of interest. However, all HIFU gener-
ators currently in clinical use are bulky (frequently20 ft3 in
total), cumbersome, and expensive, thereby hindering the
broad application of this promising technology.12
In contrast, we have developed a novel, hand-held,
battery-operated HIFU device. To our knowledge, no
peer-reviewed articles have reported the use of US in a
completely noninvasive transcutaneous fashion for the ab-
lation of pathologic veins. The purpose of this study was to
determine the efficacy of our HIFU device for completely
noninvasive venous ablation. To do so, an ex vivo testing
platform was developed to determine the ability of the
device to ablate the venous lumen without affecting sur-
rounding and intervening tissues.
MATERIALS AND METHODS
HIFU device. The HIFU device used in this study
(Fig 1) was developed in the Department of Biomedical
Engineering at Cornell University.13,14 It weighs 650 g
and is housed in a 14-  9-  4-cm watertight plastic
enclosure (No. 073; Serpac, Fareham, United Kingdom)
that contains an ultraefficient low-power US-generating
circuit and four 7.4-volt, 2200 milliampere/h lithium ion
rechargeable battery packs (No. 18650 Battery Space,
Richmond, Calif) connected in series through a dual-draw
rotary switch.15 The user can adjust power delivery to the
transducer probe to one of three settings through the
rotary switch interface in 7.4-volt increments over the
range of 14.8 volts. A battery recharge adapter at the back
of the system is wired to charge the complete system in less
than 30 minutes.
The US probe is constructed from lead zirconate titan-
Fig 1. The ultrasound device is 14 9 4 cm and weighs 650 g.
The diameter of the transducer is 3 cm.ate (PZT-4), 1.54-MHz, and 3-cm-diameter piezoelectricceramic with a radius of curvature of 3.81 cm (EBL Prod-
ucts, East Hartford, Conn). The air-backed ceramic is
housed in a polyvinyl chloride ergonomic plastic assembly
that was built on a lathe and milling system in the Depart-
ment of Biomedical Engineering. The transducer was con-
structed with multiple interchangeable clear acrylic fronts
to act as protective covers to the ceramic and focal standoffs
to allow the user to select the appropriate plane and depth
of focused US energy (Fig 2).
The portable HIFU device was calibrated with a force
balance and electroacoustic conversion factors with electri-
cal impedance spectroscopy. The device supplies continu-
ous US power and at the three different power settings,
delivers the following intensities to the focal point: low
power, 3.5 to 4 W (230-350 W/cm2), medium power, 7.8
to 8.5 W (520-790 W/cm2), and high power, 14 to 15 W
(930-1400 W/cm2).13
Testing platform. Because our current device has not
yet incorporated a visualization mode, an ex vivo testing
platform was developed that involved the sequential layer-
ing of combinations of skin, muscle, fat, and vein, which
allows for direct side-view real-time visualization. The first
Fig 2. Diagrammatic representation of ultrasound system and
transducer probe shows the three ultrasound energy standoffs. The
shorter the transducer standoff, the deeper the ultrasonic energy
penetration and focal ablation region; the longer the standoff, the
less penetration of energy.model was a combination of skin, muscle, and vein (Fig 3).
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Sprague-Dawley rat. The rat was anesthetized, shaved,
depilated, skin was removed from the ventral surface, after
which the animal was euthanized. This protocol was ap-
proved by the Weill Cornell Medical College Institutional
Animal Care and Use Committee (#0704-607A), and all
work was performed in compliance with the Guide for the
Care and Use of Laboratory Animals.16 The muscle and
vein were harvested from a lamb hind limb that was ob-
tained from a local butcher shop. A segment of muscle (3
3  3 cm) that had been cleaned to remove all traces of
fascia or fat was placed on top of the skin, and a 3-cm
segment of femoral vein was pinned in place on top of the
muscle.
The second model involved a combination of skin,
fat, and vein (Fig 4). The skin and vein were obtained in
the same fashion. Fat from a freshly slaughtered pig was
obtained from the same butcher shop. The third model
involved the same combination as in the second, except
that the vein was filled with rat blood that had been
collected after systemic anticoagulation with heparin
(200 U/kg; Fig 5).
Experimental design. To minimize resistance in
both models, the skin was thoroughly moistened with
phosphate-buffered saline (PBS), and the muscle was in-
jected with PBS (1.75 mL). The transducer was filled with
Fig 3. The skin-muscle-vein model is shown (left)
treatment. Note the lack of coagulation necrosis of the sk
the muscle that had been in direct contact with the vein
Fig 4. Skin-fat-vein model is shown (left) before ultras
the lack of coagulation necrosis of the skin (left) and fatUS transmission gel (National Medical Alliance; Carmel,Ind) placed directly beneath the skin and activated for 20
seconds, deactivated for 10 seconds, and reactivated for 20
seconds. The tissue was disassembled after each experiment
e ultrasound treatment and (right) after ultrasound
e minimal area of coagulation necrosis on the surface of
w), and the distinct contraction of the vein.
treatment and (right) after ultrasound treatment. Note
dle), and the distinct contraction of the vein (right).
Fig 5. A segment of vein in skin-fat-vein model filled with hepa-
rinized rat blood is shown (left) before and (right) after treatment
with the high-intensity focused ultrasound device.befor
in, thoundwas completed, and photographs were taken to record the
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in each model.
Tissue processing and histology. Samples of vein
that were treated with HIFU were processed for histology
by first being fixed in 10% buffered formalin for 24 hours,
then dehydrated and embedded in paraffin. Non-HIFU-
exposed controls were processed for frozen sectioning in
the same manner. Ten-micrometer sections were stained
with hematoxylin and eosin, and bright field photomicro-
graphs were taken with an upright microscope (Nikon,
Tokyo, Japan). The slides were reviewed by a blinded
pathologist from the Department of Pathology.
Luminal area measurement and statistical analysis.
The luminal cross-sectional area of vein that had been
treated withHIFU (n 6) and nontreated controls (n 6)
were measured, and values were presented as median mm2
and interquartile range (IQR). The values were compared
using a Wilcoxon rank-sum test, and statistical significance
was set at P  .05.
RESULTS
On gross examination, coagulation of the vein was
observed in the region that had been treated with HIFU
(Figs 3 and 4). The surface of the muscle in direct contact
with the vein had a pinpoint area of coagulation, whereas
the skin, fat, and the surface of the muscle in contact with
the transducer remained completely unaffected. Similar
findings were observed in the blood-filled vein, with signif-
icant contraction of the vein at the region treated with
HIFU (Fig 5).
On histologic examination, a marked narrowing of the
venous lumen was observed in the veins that had been
treated with HIFU (Fig 6). This was due to coagulative-
type necrosis and loss of elastic fibers in the adventitia, and
marked edema and constriction of the media. The skin was
Fig 6. A section of vein is shown that (left) had not been treated
with the high-intensity focused ultrasound (HIFU) device and
(right) which had been treated with HIFU. Treatment resulted in
a 96% reduction in luminal area. Hematoxylin and eosin staining at
original magnification 40.completely undamaged. The luminal cross-sectional area ofveins treated with HIFU was 0.16 mm2 (IQR, 0.04-0.39),
which was significantly different than the 3.79 (IQR, 3.38-
4.22) for untreated veins (P  .0304).
DISCUSSION
The significant disadvantage common to all currently
available minimally invasive surgical techniques for venous
ablation is that they are all, to some degree, invasive. In
response to the desire for a completely noninvasive method
for the venous ablation, we have developed a novel thera-
peutic US device, which was tested in this ex vivo study.
The results clearly indicate the effectiveness of our device in
producing a 96% reduction in venous luminal area without
affecting the intervening tissue. With a mean luminal cross-
sectional area of 0.16 mm2, we suspect that thrombosis and
complete occlusion of the vein will occur in vivo. The
qualitative gross and histologic results are impressive, and
importantly, are strengthened by the statistically significant
decrease in luminal diameter observed in veins that had
been treated with HIFU.
Furthermore, the therapeutic effect of the US energy is
not affected by the presence of blood or the proteins or
fluid content contained therein, indicating that this tech-
nology is likely to be effective in the setting of dilated,
blood-filled vessels. Because of limitations in visualization,
we were not able to test an in vivo model with flowing
blood. Such flow within the vessel may possibly change the
application parameters, and this will be a focus of our next
round of studies that incorporate a visualization mode.
The development of a transcutaneous, noninvasive
method for the treatment of varicose veins has a number of
significant challenges.17-19 The primary difficulty results
from the variable resistance of different tissues between the
transducer and the target tissue, in this case, skin, muscle,
fat, and vein, with skin having the highest resistance. The
conical pattern of the US waves is helpful in solving this
problem by having lower energy density at points closer to
the transducer. Furthermore, by incorporating PBS into
the skin and fat (by applying it to the external surface) and
muscle, the resistance of the intervening tissues was de-
creased enough to nearly eliminate any undesired collateral
thermal damage. The injection of this physiologic electro-
lyte solution is analogous to the use of tumescent solution
in liposuction and EVLT procedures, which induces both
analgesia and provides thermal insulation to the adjacent
tissues.20
The ex vivo model used in this study provides impor-
tant preliminary data to validate the use of our novel
underlying technology for the completely noninvasive ab-
lation of veins. It was designed because our current devices
lack the ability to directly visualize the target vein during
treatment. Although this represents a major limitation to
clinical application, our next-generation devices will be
capable of rapidly alternating between therapeutic and di-
agnostic (M-mode) US power levels, thereby “splicing”
together the modes and avoiding the distortion of the
visual image that results from high power levels. We believe
that accurate real-time visualization will allow the user to
JOURNAL OF VASCULAR SURGERY
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adjacent structures, including arteries and nerves.
CONCLUSIONS
Although this novel device is still a prototype, we
believe it represents a significant step forward in the devel-
opment of new applications for high-intensity, therapeutic
US technology. We believe that this relatively inexpensive,
portable device may provide clinicians with the ability to
perform venous ablation of venous varicosities and malfor-
mations in a manner that is entirely noninvasive, painless,
and logistically easily performed without the expense or
inconvenience of large, complicated devices.
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